Fig. 10 | Scientific Reports

Fig. 10

From: Cilazapril and benazepril mitigate neurodegeneration and α-synuclein accumulation in a cellular model of parkinson’s disease

Fig. 10The alternative text for this image may have been generated using AI.

MDA levels in the experimental PD model treated with cilazapril and benazepril. The effects of different doses (0.32 µM–5.12 µM) of (a) cilazapril and (b) benazepril on the cellular MDA (malondialdehyde) levels were evaluated. In the 6-OHDA-induced oxidative stress model, significantly lower MDA levels were observed in the ACE inhibitor groups than in the control, DMSO and 6-OHDA groups (*p < 0.05), **p < 0.01).

Back to article page